M PREMKUMAR

Stranger in a Strange Land

[M PREMKUMAR @docMPK]

Congratulations to Prof Goel, Prof Shalimar, Prof Aggarwal and the rntire team for a superb pra tice changing work. 💥

[Shalimar @drshalimar]

8 weeks for #HCV?
In RESOLVE, 8 weeks of sof/vel was non-inferior to 12 weeks in treatment-naive adults without cirrhosis (SVR12: 98.8% vs 99.0%). @ Amit Goel @aiims_newdelhi @SGPGI @kgmu_medical @INASL_Liver @TheLancet
https://t.co/eoACtdZx3i

[Dr Ashish Kumar @DrAshish_Kumar]

🧬 Our new paper in @JCEH_Hepatology is out!

In 69 North Indian MASLD patients genotyped for 12 candidate SNPs, we found that APOC3 and PNPLA3 operate on distinct genetic axes:

🔸 APOC3 rs2854116 — enriched in MASLD vs Indian population (OR 1.93, P<0.001) but NO fibrosis association → susceptibility variant

🔹 PNPLA3 rs738409 — strongest fibrosis predictor (OR 2.89, P=0.006) → severity variant

🔥 Carriers of risk alleles at ALL 3 loci (APOC3+PNPLA3+SAMM50) had 90% fibrosis prevalence (OR 13.7, P=0.0001)

Who gets the disease ≠ who gets worse. Ancestry-specific genetic data matter.

#MASLD #LiverTwitter #Genetics #PNPLA3 #APOC3 #Hepatology #JCEH #IndianGenomics
https://t.co/Xn6Q3HU0cj

[Nikita Sharma @sharmanik]

New issue alert ⚠️📙

Dear Readers,
The latest issue Volume 45, Issue 5 of IJG is out. Happy reading 📖🙂

#science #sciencejournal #IJG #ISG #Springer #SpringerNature #journals

https://t.co/7xxOj6W7Fr
@drvishal82 @DrAnuraagJ @IJG_Journal @UshaPGIMER @drsridhars @docMPK

[M PREMKUMAR @docMPK]

@INASL_Liver @DrAshish_Kumar @ajay_duseja @shivaramsingh @AnandVKulkarni2 @RoyAHep @giri_gutnliver Liver stiffness at SVR-48 (aHR 1.01, 95% CI: 1.001–1.030, P = 0.021) and ALBI score at
SVR-12 (aHR 1.31, 95% CI: 1.1–1.4, P = 0.034) predicted de novo HCC. Recurrence rate ⬇️patientswith de novo HCC than in those with HCC
at presemtation. 5year🇮🇳 cohort. @JCEH_Hepatology

[M PREMKUMAR @docMPK]

HCC in GT 3 HCV 🇮🇳

https://t.co/XjBZha1fJQ
De novo HCC post SVR-12 in HCV compensated cirrhosis. was in 128/3994 (3.2%), median follow-up of 4 years, an incidence of 985 per 100,000 person-years; 77.3% men, 71.6% genotype-3, BCLC stages were A (60.2%), B (28.9%), and C (10.9%).

[Anand V Kulkarni @AnandVKulkarni2]

Continuing our work on recomp-
1/3rd of AIH also can recomp.
AIH-PBC -25%
AIH-PSC none

https://t.co/U5eBx6eGMi

@RoyAHep @karanbjmc93 @docMPK @BavenoCoop @ReibergerThomas @JimmyLaiCT @TerryYip12 #LiverX

[M PREMKUMAR @docMPK]

@ebtapper @HEP_Journal Point well taken!. This was PoCUS monitored dry weight loss. Granted this may be muscle as well. A large number of the patients were obese, overweight and more than a third had LVDD.
We are now documenting muscle,subcutaneus and visceral fat and sarcopenia,..more to come.

[Akash Roy @RoyAHep]

🚨 Recompensation in decompensated AIH cirrhosis
🔹34% achieved Baveno VII recompensation
🔹 Transplant-free survival was 97% vs 63%* with vs without recompensation
🔹 20% re-decompensated
Recompensation in AIH is real but dynamic.
https://t.co/DoH5Zw5XAL

[M PREMKUMAR @docMPK]

@ajay_duseja @Nipun @AnandVKulkarni2 @BavenoCoop @RoyAHep @shivaramsingh @AASLDtweets Recompensation of decompensated cirrhosis in a spectrum of metabolic dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors. Hepatology. 2026 Jul 17. PMID: 42467948.

[M PREMKUMAR @docMPK]

https://t.co/Zx9xPrGMHw
Recompensation in MASLD/MetALD spectrum related decompensated cirrhosis with interventions for CMRF control and PEth corroborated alcohol abstinence. #livertwitter @ajay_duseja @nipun verma @AnandVKulkarni2 @BavenoCoop @RoyAHep @shivaramsingh @AASLDtweets

[Akash Roy @RoyAHep]

🇮🇳 Real-world data from &gt;1000 patients with MASLD/MetALD
MRI-PDFF phenotyping + 🧲 MRE anchor
🔍 Key takeaways:
✔️ Similar CMRF &amp; AF burden
✔️ FIB-4 &amp; NFS perform well
❌ APRI underperforms
💡 Simple NITs even for MetALD
@AnandVKulkarni2 @DrMaheshgoenka
https://t.co/4o4nXkFJ5e

[Dr Ashish Kumar @DrAshish_Kumar]

🧵NEW STUDY PUBLISHED
Our DiaFib-Liver Study is now published in @LancetRH_SEAsia.
The largest-ever real-world survey of liver fibrosis in type 2 diabetes from any low- or middle-income country.
9,202 patients. 82 doctors. Pan-India. 🇮🇳
🔗 https://t.co/DPVtTIMifK

[Dr Ashish Kumar @DrAshish_Kumar]

#Fibrosis prevalence across clinical subgroups:
Highest: CAD (33%),
eGFR &lt;60 (33%),
Obesity (32%),
Dyslipidaemia (30%)
Even without obesity: 19%
Dashed line = overall prevalence (26%).
No difference by sex or hypothyroidism.
Fibrosis is widespread across ALL subgroups.

[M PREMKUMAR @docMPK]

@anjan_dhar6 @IJG_Journal @UshaPGIMER @drvishal82 @drsridhars @SChandanMD @BabuPMohan2 @Samanta_JayPGI @elhence_anshu @ibdseb @amolbapaye @ZaheerNabi8 @miNitinjagtap @GKochharMD https://t.co/MdXVKDjZGI

[Nikita Sharma @sharmanik]

*New Issue Alert*
The special IJG Women and Gastroenterology March-April issue (Volume 45, Issue 2) is online.
Please have a look:
https://t.co/ZBke1qpJME

@IJG_Journal @docMPK @drvishal82 @drsridhars @DrAnuraagJ @giri_gutnliver @UshaPGIMER

[Indian Journal of Gastroenterology @IJG_Journal]

Gastro-intestinal infections and stewardship practices—A call for action to practising GI professionals

Rohit Gupta et al

https://t.co/wJIsY9Bk5C

[M PREMKUMAR @docMPK]

@IvaKosuta Thanks Iva!! Hope to see you work with us on the next one.🗺 prospective data needed.

[M PREMKUMAR @docMPK]

@giri_gutnliver @KIMSGastro @hsid_h @RoyAHep @drsridhars @AnandVKulkarni2 @DrAnuraagJ @KailashKolhe @drgauravkhatana Congratulations Giri

[Indian Journal of Gastroenterology @IJG_Journal]

MUST-READ REVIEW

Gastrointestinal cancers in women: The role of sex hormones

by Amit Yadav &amp;
Prof Usha Dutta @UshaPGIMER

#WomenGI #GItwitter

https://t.co/SHkGUyFpl5